August 13, 2026

To,
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai - 400001
Script Code – 540737

Sub: Press Release.

With reference to the captioned subject, we enclose herewith the Press Release with respect to Unaudited Financial Results of the Company for the quarter ended June 30, 2026.

Kindly take the same on your record.

Thanking You,

Yours faithfully,
For Shree Ganesh Remedies Limited

ADITYA VIKRAMBHAI PATEL
Digitally signed by ADITYA VIKRAMBHAI PATEL
Date: 2026.08.13 12:30:27 +05'30'

Aditya Patel
Company Secretary

Enc. a/a

SHREE GANESH REMEDIES LIMITED REPORTS Q1FY27 RESULTS

Ankleshwar, August 12th, 2026: Shree Ganesh Remedies Limited, one of the fastest growing CMO & CDMO based in India for Pharmaceutical Intermediates & Fine Chemicals, announced its financial results for Q1FY27.

Financial Highlights for Quarter Ended June 30th, 2026:

(₹ In crore & %)

REVENUE	EBITDA	PAT	EBITDA MARGINS
14.36 Cr.	**3.35 Cr.**	**1.12 Cr.**	**23.3%**
-42% YoY	**-54% YoY**	**-68% YoY**	**-624 BPS YoY**
11.49 Cr. Revenue from Pharma Intermediates in Q1FY27	**2.88 Cr.** Revenue from Speciality Chemicals in Q1FY27	**8.64 Cr.** Revenue from Exports in Q1FY27	**5.72 Cr.** Revenue from Domestic Sales in Q1FY27

Commenting on the results, Mr. Gunjan Kothia, Promoter said:

Q1FY27 has been a challenging quarter for the Company. European demand has continued to remain subdued, with a meaningful number of customers deferring orders amidst the ongoing geopolitical uncertainty and considerable volatility in raw material markets. This has had a direct bearing on our topline and profitability for the quarter, and I would note that the subdued demand environment has persisted into the early part of Q2FY27 as well.

Additionally, during the quarter, our marketing and manufacturing agreement with one of our EU distributors reached its automatic termination owing to non-performance as per the agreed terms of the commercial agreement. This opens the way for the Company to engage directly with customers, giving us greater control over these relationships and the opportunity to develop them on our own terms. We expect this transition to take a couple of quarters before volumes are meaningfully restored, and we remain confident of returning to our prior run-rate levels in the second half of the financial year.

On the CRAMS front, our engagements in South-East Asia continue to progress in line with our expectations and timelines, and we anticipate these projects beginning to contribute to revenues from H2FY27.

Given the unexpected persistence of geopolitical headwinds, customer caution, and a visibly softer first half, we believe it is appropriate to moderate our earlier guidance of FY27 being a year of non-linear growth. The CRAMS pipeline remains firmly on track, Block 7 remains on course for commissioning, and the strategic direction of the business has not changed. The strategies we have laid out are being executed with the same rigour and intent. What we are navigating is a timing issue. The foundations we have built over the past year or more remain intact, and we are confident that the second half of FY27 will reflect a meaningful improvement in performance as these catalysts progressively come online.

We remain steadfast in our belief that patient, disciplined execution on the right strategic priorities will deliver a stronger and more profitable business over the medium to long term.

SHREE GANESH REMEDIES LIMITED
excelling in chemistry

Financial Highlights:

PARTICULARS (₹ IN CRORES)	Q1FY26	Q4FY26	Q1FY27	YoY Change	QoQ Change
Revenue from Operations	**24.67**	**33.20**	**14.36**	**-42%**	**-57%**
Total Income	25.33	34.22	15.30	-40%	-55%
Operating Expenses	17.37	21.87	11.01	-37%	-50%
EBITDA (Excluding OI & EI)	**7.30**	**11.37**	**3.35**	**-54%**	**-71%**
EBITDA %	**29.6%**	**34.3%**	**23.3%**	**-624 bps**	**-1,092 bps**
Finance Cost	0.94	0.88	0.32	-66%	-64%
Depreciation & Ammortization	2.42	2.80	2.44	1%	-13%
PBT	4.60	8.72	1.53	-67%	-82%
PAT	**3.45**	**6.27**	**1.12**	**-68%**	**-82%**
EPS (₹)	2.69	4.88	0.87	-68%	-82%

About Shree Ganesh Remedies Limited: (SGRL)

Shree Ganesh Remedies Limited is a leading player in the chemical manufacturing industry, specialising in pharmaceutical intermediates and specialty chemicals. With over 19 years of excellence, the company is renowned for its unparalleled expertise in advanced chemical synthesis and complex chemical reactions. Strategically expanding its operations, Shree Ganesh Remedies is focused on innovation through strategic R&D investments and state-of-the-art infrastructure. The company serves over 20 countries, including key markets in the EU and the US, offering tailored solutions to global industry leaders. Committed to sustainable practices, Shree Ganesh Remedies holds multiple accreditations, including ISO certifications and EcoVadis Bronze. With ongoing expansions at its Ankleshwar and Dahej sites and a strategic shift towards complex niche specialty chemicals, the company is well-positioned for future growth and continues to deliver high-quality, custom manufacturing solutions to its clients.

Contact us:

Aditya Patel
Company Secretary
Shree Ganesh Remedies Limited
Email: investors@ganeshremedies.com

Abhishek Mehra
Investor Relations Advisors
TIL Advisors Private Limited
Email: abhishek@theinvestmentlab.in
Mobile No.: +91 95588 14500